A group of senators asked the Government Accountability Office to review the FDA's policy of allowing medical experts with financial ties to drug and medical-device manufacturers to serve on FDA advisory panels. The practice of granting waivers for such experts appears to have "undermined the public's faith in the objectivity and fairness of FDA's advisory committees," the senators said.

Related Summaries